Professor Tomas Olsson
Professor Tomas Olsson, MD, PhD has been involved in research in the neurology field for more than 40 years. Tomas Olsson is Professor in Neurology at Karolinska Institutet, Sweden since 2008.
Prof. Olsson is a member and co-founder of the Swedish Multiple Sclerosis Society as well as a member of multiple international MS societies. Prof. Olsson is a board member and co-founder of the European school of Neuroimmunology (ESNI), member of the international scientific board of the international congress of Neuroimmunology (ISNI), former executive board member of the international scientific board of the European committee for the treatment of MS. (ECTRIMS) and member of the International Multiple Sclerosis Genetics Consortium (IMSGC).
Prof. Olsson’s research focus on neuroinflammation with focus on multiple sclerosis (MS), and its relation to genetics, immunology and life style/environmental factors. He has authored over 600 papers published in peer reviewed journals.
Professor Bengt Winblad
Professor Bengt Winblad, MD, PhD has been involved in the field of dementia research for almost 50 years. Bengt Winblad is Professor of Geriatric Medicine at Karolinska Institutet and part of the Clinical Trial Center (which he established in 1987) at Karolinska University Hospital in Huddinge. He was a member of the Nobel Assembly 1988 – 2008. BW has held multiple international positions. He chaired the European Alzheimer Disease Consortium (EADC) 2000 – 2019 and the Medical Scientific Advisory Panel (MSAP) of the Alzheimer Disease International (ADI) for ten years. BW started the International Alzheimer Conference (ICAD) – now AAIC, which he transferred to Alzheimer’s Association in 2002. He also started the International PharmacoEconomic Conference on Alzheimer Disease (IPECAD).
Prof. Winblad´s research focus is on drug discovery and treatment of patients with Alzheimer disease. BW has published more than 1000 original publications in the field of gerontology/geriatrics/dementia research and treatment of dementia conditions, especially Alzheimer disease.
Professor Henrik Zetterberg
Henrik Zetterberg is Professor in Neurochemistry at the University of Gothenburg, Sweden, and University College London, UK, and a Clinical Chemist at Sahlgrenska University Hospital in Gothenburg. Prof. Zeterberg is Head of the Department of Psychiatry and Neurochemistry at the University of Gothenburg and leads the UK DRI Fluid Biomarker Laboratory at UCL. He is also chair of the Swedish Alzheimer’s Foundation Scientific Council and is a leading global authority in the field of biomarkers related to neurodegenerative diseases.
Prof. Zetterberg’s main research focus and clinical interest are fluid biomarkers for central nervous system diseases, Alzheimer’s disease in particular. He has published more than 1200 papers and has received numerous awards.
AMRI, a global contract research, development and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life. AMRI combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical Services, API Manufacturing and Drug Product.
Amsterdam Neuroscience is the neuroscience research institute of Amsterdam UMC and the science faculties of Vrije Universiteit Amsterdam and the University of Amsterdam. Researchers and clinicians from these three institutions join forces in the field of fundamental, translational and clinical brain research. This strengthens the scientific excellence in this area, making Amsterdam Neuroscience one of the largest neuroscience communities in Europe. The overall mission is to broaden the fundamental knowledge of the human brain and nervous system, and to translate this into effective therapies and treatments for the individual patient.
Bachem is an independent, innovation-driven, public company providing full service to the pharma and biotech industry. The compnay is specialized in the process development and the manufacturing of peptides and oligonucleotides as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes.
Captario is a Gothenburg based software company developing SUM™ – Strategic Uncertainty Management, a game-changing SaaS platform enabling leading companies to optimize decision making.
SUM combines advanced modeling, simulation, analytics, visualization, and reporting workflows in one seamless solution for decision making in both projects & portfolios. SUM empowers users to make more dynamic, impactful, and profound decision by assessing practically all possible futures.
CRST is a contract research organization (CRO) that conducts clinical studies for the pharmaceutical industry and for other customers. CRST is run by experienced specialists with in-depth understanding of basic and clinical pharmacology and drug development, especially in therapeutic areas such as disorders of the central nervous system and metabolic and cardiovascular diseases.
Specialists from different fields participate in CRST’s operations as principal investigators and scientific consultants. Thanks to its close cooperation with Turku PET Centre, CRST is equipped to perform clinical proof-of-concept studies involving PET imaging.
Leads To Development
Leads To Development (L2D) is a privately owned company that was formed to create a high value service that provides support for clients developing innovative drugs.
The services span all stages of the drug development process, but are often focused on the earlier stages: from the discovery of a candidate new drug up to and including the first tests in humans.
Scandinavian Development Services
Scandinavian Development Services (SDS) is a Swedish Consultancy focusing on regulatory and scientific expertise within drug development and biostatistics. The major assets are the staff, all of whom have a long working experience of drug development from the pharmaceutical industry, regulatory authorities and/or academic research.
SDS offers clients a unique and complete concept consisting of both specialist competence and overall responsibility for specific sections of or alternatively a whole project.